KOPRAN
|
The Current P/E Ratio of KOPRAN is 23.47.
| Share Price | ₹169.7 | Oct 23,2025 |
| Market Cap | ₹819.4 Cr | |
| Earnings-TTM | ₹34.9 Cr | TTM-Consolidated Results |
| Price/Earnings | 23.47x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of KOPRAN
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹819.4 Cr] as on Oct 23,2025
(/) Earnings [ ₹34.9 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 23.47x ]
Thus, for KOPRAN , the investors are currently willing to pay 23.47 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of KOPRAN !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of KOPRAN over the last five years.
Historical PE (Price/Earnings) ratio chart of KOPRAN
PE Ratio Performance Analysis for KOPRAN
- KOPRAN 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.11x.
- KOPRAN 's operated at median p/e ratio of 21.93x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, KOPRAN 's p/e ratio peaked in Mar2024 at 24.45x.
- KOPRAN 's p/e ratio hit its five-year low in Mar2021 of 7.37x.
How does KOPRAN 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| KOPRAN | 34.91 | 23.47 | 819.4 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,411.50 | 38.92 | 405,248.0 |
| DIVIS LABORATORIES LTD | 2,306.00 | 75.53 | 174,177.0 |
| CIPLA LTD | 5,406.81 | 24.58 | 132,898.0 |
| TORRENT PHARMACEUTICALS LTD | 2,002.00 | 61.15 | 122,428.0 |
| DR REDDYS LABORATORIES LTD | 5,726.70 | 18.65 | 106,818.0 |
| MANKIND PHARMA LTD | 1,905.51 | 53.05 | 101,095.0 |
| ZYDUS LIFESCIENCES LTD | 4,637.80 | 21.87 | 101,408.0 |
| LUPIN LTD | 3,722.18 | 23.81 | 88,616.1 |
| AUROBINDO PHARMA LTD | 3,417.93 | 18.67 | 63,827.2 |
| ABBOTT INDIA LTD | 1,452.29 | 44.04 | 63,959.3 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs KOPRAN 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.65x |
| Max industry PE | 75.53x |
| Median industry PE | 24.58x |
| Average industry PE | 36.70x |
You may also like the below Video Courses